Compare UiPath Inc (PATH) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs BIO-TECHNE Corp — how do they compare? UiPath Inc trades at $13.44 (market cap $6.91B), while BIO-TECHNE Corp trades at $72.44 (market cap $11.36B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while UiPath Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold UiPath Inc for 139 Days and BIO-TECHNE Corp for 64 Days on average.
| PATH | TECH | |
|---|---|---|
Market Cap | $6.91B | $11.36B |
Volume | 34,321,250 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $19.29 | $72.61 |
52-Week Low | $9.38 | $43.31 |
Typical Hold Time | 139 Days | 64 Days |
Enterprise Value | $5.70B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $13.45, up 2.87% today, showing technical bullish momentum despite mixed earnings. The company demonstrates strong revenue growth from $1.43B in 2025 to projected $1.7B in 2026, with net income turning positive at $362M. Recent partnerships with Snowflake and BDO highlight strategic expansion in AI orchestration, while analyst consensus remains cautious with 67% hold ratings.
PATH offers growth potential through AI automation leadership but faces execution risks amid competitive pressures. The stock trades below consensus target of $15.13, suggesting 12% upside if guidance is met. Key risks include pricing pressure and integration challenges with new partnerships.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
